Osteopan series MultiVita

Dosage form Application area Recommendations for use Contraindications Manufacturer
Read on
Certificate number:RU.77.99.11.003.E.051241.11.11
Date of registration and renewal:17.11.2011
Dosage form: & nbspTableti with a mass of 1490.0 mg ± 74.5 mg
Classification "Composition" & nbsp Dietary supplements - proteins, amino acids and their derivatives Supplements - vitamins, vitamin-like substances and coenzymes BAD - products of plant, animal or mineral origin
Classification "Clinical" & nbsp BAD-source of monovitamins and vitamin-like substances BAD-sources of mineral substances Supplements containing zinc, copper, manganese Supplements containing calcium and phosphorus Supplements containing potassium and magnesium
Composition: & nbspComposition: calcium (calcium carbonate, calcium hydrogen phosphate, calcium lactate, calcium citrate), magnesium oxide, zinc gluconate, cholecalciferol Auxiliary components: corn starch, carboxymethyl cellulose sodium salt (E466), silica (E551), shellac (E904), magnesium stearate (E470), hydroxypropylmethylcellulose (E464), MCC (E460), titanium dioxide (E171), talc (E553), olive oil
Scope: & nbspDFor distribution to the population through the pharmacy network and specialized stores, the sales network departments as a biologically active food additive - an additional source of magnesium, calcium, zinc, vitamin D (ANNEX)
Suggested Usage: & nbspAT1 tablet 1-3 times a day with meals, with 1 glass (200 ml) of water. Duration of admission is 1 month. If necessary, the reception can be repeated.
Contraindications:ANDindividual intolerance of components, pregnancy, breast-feeding. Do not allow simultaneous reception with iron preparations (the interval between doses is not less than 2-3 hours).
Special instructions:Before use, it is recommended to consult a doctor.
Shelf life:3 years.
Storage conditions:Store in a dry place, protected from light, out of reach of children, at a temperature not exceeding + 25 ° ะก.
Research protocols:EThe Federal Agency for the Federal Treasury and Federal Service for Consumer Rights Protection No. 10-2FTS / 2000 dated April 19, 2010
Recipient:HEMOFARM JOINT STOCK COMPANY PHARMACEUTICAL AND CHEMICAL INDUSTRYHEMOFARM JOINT STOCK COMPANY PHARMACEUTICAL AND CHEMICAL INDUSTRY
Information update date: & nbsp14.07.2016
Instructions
Up